Last Updated: May 11, 2026

Details for New Drug Application (NDA): 212887

✉ Email this page to a colleague

NDA 212887 describes VOCABRIA, which is a drug marketed by Viiv Hlthcare and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the VOCABRIA profile page.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this compound. Additional details are available on the cabotegravir sodium profile page.

Summary for 212887

Tradename:	VOCABRIA
Applicant:	Viiv Hlthcare
Ingredient:	cabotegravir sodium
Patents:	2

Pharmacology for NDA: 212887

Mechanism of Action	HIV Integrase Inhibitors Organic Anion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors

Suppliers and Packaging for NDA: 212887

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887	NDA	ViiV Healthcare Company	49702-248	49702-248-13	30 TABLET, FILM COATED in 1 BOTTLE (49702-248-13)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 30MG BASE
Approval Date:	Jan 21, 2021	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Jan 21, 2026
Regulatory Exclusivity Use:	NEW CHEMICAL ENTITY
Patent:	10,927,129	Patent Expiration:	Apr 28, 2026	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patent:	8,410,103	Patent Expiration:	Feb 4, 2031	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG

Expired US Patents for NDA 212887

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	VOCABRIA	cabotegravir sodium	TABLET;ORAL	212887-001	Jan 21, 2021	10,927,129	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.